Sonoma Pharmaceuticals
SNOA
16 hedge funds and large institutions have $396K invested in Sonoma Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0.01% less ownership
Funds ownership: 0.3% → 0.29% (-0.01%)
6% less funds holding
Funds holding: 17 → 16 (-1)
31% less capital invested
Capital invested by funds: $574K → $396K (-$178K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$21.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$21.4K |
| 3 |
Renaissance Technologies
New York
|
-$1.17K |
| 4 |
HFS
HBC Financial Services
Seattle,
Washington
|
-$469 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $161K | -$1.17K | -20 | -0.5% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $78K | – | – | – |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $72K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $39K | -$21.4K | -366 | -29% |
|
|
HFS
5
HBC Financial Services
Seattle,
Washington
| $17K | -$469 | -8 | -44% |
|
|
6
UBS Group
Zurich,
Switzerland
| $12K | +$14.1K | +241 | +709% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $10K | +$12.9K | +220 | +846% |
|
8
BlackRock
New York
| $6K | – | – | – |
|
9
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
10
Bank of America
Charlotte,
North Carolina
| – | -$21.6K | -369 | -99% |
|
SNOA Hedge Fund Activity: Q3 2022 in Review
16 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q3 2022, worth a combined $396K — down 31% from $574K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SNOA and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $14.1K. The largest seller was Bank of America, cutting an estimated $21.6K.
- 16 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q3 2022, down from 17 in Q2 2022.
- Funds reported $396K of Sonoma Pharmaceuticals stock for Q3 2022, down 31% quarter-over-quarter.
- 0 funds opened new Sonoma Pharmaceuticals positions in Q3 2022 and 1 closed out, a net change of -1 holder.
- The largest Sonoma Pharmaceuticals buyer in Q3 2022 was UBS Group, an estimated $14.1K added.
- The largest Sonoma Pharmaceuticals seller in Q3 2022 was Bank of America, an estimated $21.6K sold.
Based on aggregated 13F filings for Q3 2022.